The US Patent Trial and Appeal Board (PTAB) has decided that the Saint Regis Mohawk Tribe cannot claim sovereign immunity from inter partes review (IPR) of Allergan’s patents covering Restasis, and that the IPR proceedings on those patents can continue with Allergan as the patent owner.
The US Patent Trial and Appeal Board (PTAB) has decided that the Saint Regis Mohawk Tribe cannot claim sovereign immunity from inter partes review (IPR) of Allergan’s patents covering Restasis, and that the IPR proceedings on those patents can continue with Allergan as the patent owner.
The decision stems from Allergan’s 2017 transfer of patents covering its dry-eye drug to the Tribe in exchange for invoking sovereign immunity from IPRs. The move came less than 1 week before a scheduled oral hearing for several instituted IPRs of patents covering Restasis. The Tribe then moved to dismiss the scheduled proceedings for lack of jurisdiction.
After considering numerous amicus briefs (and the supplemental briefs of both the petitioners and the patent owners), the PTAB determined that “…the Tribe has not established that the doctrine of tribal sovereign immunity should be applied to these proceedings. Furthermore, we determine that these proceedings can continue even without the Tribe’s participation in view of Allergan’s retained ownership interests in the challenged patents.”
Among the reasons for its decision, says the PTAB, is that tribal sovereignty is subject to the superior control of Congress, and that acts of Congress apply to tribes. Thus, since Congress has enacted a statute that stipulates that any patent is subject to the requirements of law, including IPRs, tribal ownership of a patent does not shield the owner from an IPR proceeding.
Furthermore, the PTAB agreed with the petitioners in their claim that Allergan is the true owner of the patents in question, regardless of how Allergan and the Tribe characterized their arrangement. The PTAB addresses the following among its reasons for the decision:
However, the PTAB did not address the question of whether the arrangement between the Tribe and Allergan was proper; in October 2017, Judge William C. Bryson, who presided over an unrelated Hatch-Waxman litigation concerning Restasis, called for briefs addressing “…whether the assignment of the patents to the Tribe should be disregarded as a sham.” Bryson later invalidated the patents in question in this case.
In its decision, the PTAB wrote that, “In reaching this conclusion, we do not comment on whether the License and the other agreements between the Tribe and Allergan constitute a ‘sham’ transaction, nor do we need to decide whether the agreements are otherwise improper under the law.”
Skyrizi Overtakes Humira: “Product Hopping” Leaves Biosimilar Market in Limbo
November 7th 2024For the first time, Skyrizi (risankizumab-rzaa) has replaced Humira (reference adalimumab) as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
BioRationality: Should mRNA Copies Be Filed as NDAs or Biosimilars?
November 4th 2024The article by Sarfaraz K. Niazi, PhD, argues that the FDA’s classification of future copies of messenger RNA (mRNA) products could be reconsidered, suggesting they might be eligible for new drug applications (NDAs) or a hybrid biosimilar category due to their unique characteristics and increasing prevalence.
Panelists Stress Stakeholder Education to Build Confidence in Biosimilars
October 31st 2024By expanding educational initiatives to clarify biosimilar safety, efficacy, and interchangeability, stakeholders can foster trust, improve access, and ensure that biosimilars are widely accepted as high-quality, cost-effective alternatives to originator biologics.
Enhancing Adoption of Infused Biosimilars for a Sustainable Future
October 30th 2024An IQVIA report highlights challenges to the sustainability of infused biosimilars in the US, citing rebate walls and reimbursement policies, and proposes key solutions to enhance adoption and benefits for all stakeholders.